Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against
human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII …

OBI‐1 is a recombinant B‐domain deleted porcine factor VIII (FVIII). FVIII treatment in those
with haemophilia A may be complicated by the development of anti‐FVIII antibodies …

Background Recombinant porcine factor VIII (rpFVIII, OBI‐1, susoctocog alfa) is used for the
treatment of acute bleeds in patients with acquired hemophilia A (AHA). Inhibitors in AHA …

Introduction A recombinant porcine factor VIII B‐domain‐deleted product (rp FVIII; OBIZUR,
Baxalta Incorporated, Deerfield, IL 60015, USA) was recently approved for treatment of …

Introduction BAY 81‐8973 (Kovaltry®) is a full‐length, unmodified recombinant human factor
VIII (FVIII) with the same amino acid sequence as sucrose‐formulated recombinant FVIII and …

Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor)
to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe …

To add an increased level of safety to antihemophilic factor replacement therapy, a full-
length, recombinant Factor VIII (rFVIII) product has been developed without human-derived …

Background In patients with severe hemophilia A, standard treatment is regular prophylactic
and episodic intravenous infusions of factor VIII. However, these treatments are …

A cohort of 79 previously untreated patients (PUPs) with moderatesevere haemophilia A
(baseline Factor VIII< 2%) were enrolled in a study to evaluate the safety, efficacy and …

Introduction Nuwiq®(Human‐cl rh FVIII) is a new‐generation recombinant factor VIII (rFVIII)
protein, without chemical modification or fusion to any other protein, produced in a human …